GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » ROE %
中文

Aroa Biosurgery (ASX:ARX) ROE %

: -12.63% (As of Sep. 2023)
View and export this data going back to 2020. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Aroa Biosurgery's annualized net income for the quarter that ended in Sep. 2023 was A$-11.72 Mil. Aroa Biosurgery's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was A$92.81 Mil. Therefore, Aroa Biosurgery's annualized ROE % for the quarter that ended in Sep. 2023 was -12.63%.

The historical rank and industry rank for Aroa Biosurgery's ROE % or its related term are showing as below:

ASX:ARX' s ROE % Range Over the Past 10 Years
Min: -30.26   Med: -10.6   Max: -0.39
Current: -8.31

During the past 4 years, Aroa Biosurgery's highest ROE % was -0.39%. The lowest was -30.26%. And the median was -10.60%.

ASX:ARX's ROE % is ranked worse than
57.95% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs ASX:ARX: -8.31

Aroa Biosurgery ROE % Historical Data

The historical data trend for Aroa Biosurgery's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23
ROE %
- -30.26 -10.60 -0.39

Aroa Biosurgery Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
ROE % Premium Member Only Premium Member Only -12.82 -6.15 3.05 -3.82 -12.63

Competitive Comparison

For the Medical Devices subindustry, Aroa Biosurgery's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aroa Biosurgery ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's ROE % distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's ROE % falls into.



Aroa Biosurgery ROE % Calculation

Aroa Biosurgery's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-0.371/( (93.402+95.377)/ 2 )
=-0.371/94.3895
=-0.39 %

Aroa Biosurgery's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-11.718/( (95.377+90.252)/ 2 )
=-11.718/92.8145
=-12.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


Aroa Biosurgery  (ASX:ARX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-11.718/92.8145
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-11.718 / 57.95)*(57.95 / 106.8315)*(106.8315 / 92.8145)
=Net Margin %*Asset Turnover*Equity Multiplier
=-20.22 %*0.5424*1.151
=ROA %*Equity Multiplier
=-10.97 %*1.151
=-12.63 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-11.718/92.8145
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-11.718 / -11.456) * (-11.456 / -17.636) * (-17.636 / 57.95) * (57.95 / 106.8315) * (106.8315 / 92.8145)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0229 * 0.6496 * -30.43 % * 0.5424 * 1.151
=-12.63 %

Note: The net income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Aroa Biosurgery ROE % Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aroa Biosurgery (ASX:ARX) Business Description

Traded in Other Exchanges
N/A
Address
64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines